Biondo Investment Advisors LLC Acquires 4,620 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Biondo Investment Advisors LLC increased its stake in TransMedics Group by 8.6%, owning 58,070 shares after acquiring an additional 4,620 shares, valued at approximately $3.9 million.
• Several research firms have raised their price targets for TransMedics Group, with Oppenheimer increasing it to $150.00 and Morgan Stanley to $123.00, highlighting strong institutional interest in the stock.
• TransMedics Group reported a significant 37.7% year-over-year revenue increase in its recent earnings, with earnings per share of $0.92 exceeding analyst expectations.

Biondo Investment Advisors LLC lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 8.6% in the first quarter, according to its most recent filing with the SEC. The fund owned 58,070 shares of the company's stock after acquiring an additional 4,620 shares during the period. Biondo Investment Advisors LLC owned approximately 0.17% of TransMedics Group worth $3,907,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. NBC Securities Inc. bought a new stake in TransMedics Group in the first quarter worth $25,000. Hager Investment Management Services LLC lifted its stake in TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after purchasing an additional 205 shares during the last quarter. CWM LLC lifted its stake in TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after purchasing an additional 155 shares during the last quarter. AlphaQuest LLC lifted its stake in TransMedics Group by 55.6% in the first quarter. AlphaQuest LLC now owns 1,288 shares of the company's stock worth $87,000 after purchasing an additional 460 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after purchasing an additional 1,324 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the transaction, the director directly owned 2,866 shares of the company's stock, valued at $362,405.70. This represents a 63.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares of the company's stock, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on TMDX shares. Morgan Stanley boosted their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Piper Sandler reissued an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $123.00.

TransMedics Group Trading Down 4.1%

TMDX stock traded down $4.88 during trading on Monday, reaching $114.97. The company had a trading volume of 904,946 shares, compared to its average volume of 1,260,528. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.00. The company has a market cap of $3.92 billion, a P/E ratio of 59.57 and a beta of 2.09. The business has a 50 day moving average of $121.11 and a 200 day moving average of $102.00. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. During the same period in the prior year, the firm earned $0.35 earnings per share. TransMedics Group's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.